SNX-5422 + erlotinib

SNX-5422 + erlotinib is an investigational combination therapy consisting of SNX-5422, an orally bioavailable prodrug of the small molecule Hsp90 inhibitor SNX-2112, and erlotinib, a tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). SNX-5422 inhibits Hsp90 by binding to its N-terminal ATP pocket, leading to degradation of multiple oncogenic client proteins involved in cancer cell survival and proliferation. Erlotinib blocks EGFR signaling by inhibiting its tyrosine kinase activity. The combination has been studied primarily in non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations or acquired resistance to EGFR inhibitors. Preclinical studies demonstrated that this combination can inhibit key signaling pathways (such as pAKT, pSTAT3, pERK1/2) and prolong survival in xenograft models resistant to EGFR inhibitors[2]. Early-phase clinical trials have shown that the regimen is generally well tolerated at defined dose levels[3].